62932-94-9

Basic information

• Product Name: 2-BROMO-1-[4-HYDROXY-3-(HYDROXYMETHYL)PHENYL]ETHAN-1-ONE
• Synonyms: 2-BROMO-1-[4-HYDROXY-3-(HYDROXYMETHYL)PHENYL]ETHAN-1-ONE;2-Bromo-4-hydroxy-3-(hydroxymethyl)acetophenone;Ethanone, 2-broMo-1-[4-hydroxy-3-(hydroxyMethyl)phenyl]-;2-broMo-1-(4-hydroxy-3-(hydroxyMethyl)phenyl)ethanone;2-broMo-1-[4-hydroxy-3-(hydroxy
• CAS NO: 62932-94-9
• Molecular Formula: C₉H₉BrO₃
• Molecular Weight: 245.07
• EINECS: 810-683-4
• Product Categories: Intermediate
• Mol File: 62932-94-9.mol

Chemical Properties

• Boiling Point: 349.4±11.0 °C(Predicted)
• Appearance: /
• Density: 1.674±0.06 g/cm3(Predicted)
• Storage Temp.: -20°C Freezer, Under inert atmosphere
• Solubility: DMSO (Slightly), Methanol (Slightly)
• PKA: 7.69±0.20(Predicted)
• Stability: Not Stable in Solution
• CAS DataBase Reference: 2-BROMO-1-[4-HYDROXY-3-(HYDROXYMETHYL)PHENYL]ETHAN-1-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-BROMO-1-[4-HYDROXY-3-(HYDROXYMETHYL)PHENYL]ETHAN-1-ONE(62932-94-9)
• EPA Substance Registry System: 2-BROMO-1-[4-HYDROXY-3-(HYDROXYMETHYL)PHENYL]ETHAN-1-ONE(62932-94-9)

Safety Data

• Hazardous Substances Data: 62932-94-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-Bromo-1-[4-hydroxy-3-(hydroxymethyl)phenyl]ethanone is used as a reagent for the design of haptens in the pharmaceutical industry. The primary application reason for its use is to create highly sensitive and specific monoclonal antibodies for the screening of salbutamol, a widely used bronchodilator medication. This allows for accurate detection and monitoring of salbutamol levels in various applications, such as sports doping tests and therapeutic drug monitoring.

Preparation

Obtained by treatment of its diacetate with 1 N hydrogen bromide in tetrahydrofuran at 75°.

InChI:InChI=1S/C9H9BrO3/c10-4-9(13)6-1-2-8(12)7(3-6)5-11/h1-3,11-12H,4-5H2

Synthetic route

5-(2-bromoacetyl)-2-hydroxybenzaldehyde (115787-50-3) → 2-bromo-1-[4-hydroxy-3-(hydroxymethyl)-phenyl]ethanone (62932-94-9)

Conditions	Yield
Stage #1: 5-(2-bromoacetyl)-2-hydroxybenzaldehyde With propionic acid In tetrahydrofuran at 5 - 10℃; for 0.5h; Stage #2: With sodium tetrahydroborate In tetrahydrofuran at 0 - 5℃; for 1h; Solvent; Reagent/catalyst;	94%
With sodium tetrahydroborate; acetic acid at 0 - 20℃; Inert atmosphere;	88%
With sodium tetrahydroborate; acetic acid at 8 - 20℃;	85%
With sodium tetrahydroborate; acetic acid at 10℃; for 1h;	85%
With sodium tetrahydroborate; acetic acid at 25℃; for 1h;	80%

3'-acetoxymethyl-4'-acetoxy-2-bromoacetophenone (24085-07-2) → 2-bromo-1-[4-hydroxy-3-(hydroxymethyl)-phenyl]ethanone (62932-94-9)

Conditions	Yield
With hydrogen bromide In tetrahydrofuran at 75℃;
With hydrogen bromide In methanol; water
With hydrogen bromide In methanol; water

4'-acetoxy-3'-(acetoxymethyl)acetophenone (24085-06-1) → 2-bromo-1-[4-hydroxy-3-(hydroxymethyl)-phenyl]ethanone (62932-94-9)

Conditions	Yield
Multi-step reaction with 2 steps 1: polyvinylpyridinium bromide perbromide resin / CH2Cl2 2: 1N HBr / tetrahydrofuran / 75 °C View Scheme

4-Hydroxyacetophenone (99-93-4) → 2-bromo-1-[4-hydroxy-3-(hydroxymethyl)-phenyl]ethanone (62932-94-9)

Conditions	Yield
Multi-step reaction with 3 steps 1.1: resin-bound piperazinomethylpolystyrene / H2O; tetrahydrofuran 1.2: 14 percent / pTSA / toluene / 110 °C 2.1: polyvinylpyridinium bromide perbromide resin / CH2Cl2 3.1: 1N HBr / tetrahydrofuran / 75 °C View Scheme

salicylaldehyde (90-02-8) → 2-bromo-1-[4-hydroxy-3-(hydroxymethyl)-phenyl]ethanone (62932-94-9)

Conditions	Yield
Multi-step reaction with 2 steps 1: aluminum (III) chloride / dichloromethane / 15 h / Reflux 2: sodium tetrahydroborate; acetic acid / 1 h / 10 °C View Scheme
Multi-step reaction with 2 steps 1.1: aluminum (III) chloride / dichloromethane / 0.5 h / 50 °C 1.2: 12 h / 40 °C 2.1: sodium tetrahydroborate; acetic acid / 0 - 20 °C / Inert atmosphere View Scheme
Multi-step reaction with 2 steps 1.1: aluminum (III) chloride / dichloromethane / 0.5 h / 10 - 30 °C 1.2: 24 h / 35 °C 2.1: acetic acid; sodium tetrahydroborate / 1 h / 25 °C View Scheme

2-Methoxypropene (116-11-0) + 2-bromo-1-[4-hydroxy-3-(hydroxymethyl)-phenyl]ethanone (62932-94-9) → 2-bromo-1-(2,2-dimethyl-4H-benzo[d][1,3]dioxin-6-yl)ethanone (102293-80-1)

Conditions	Yield
With toluene-4-sulfonic acid In dichloromethane at 0℃; for 0.666667h;	100%
With resin-SO3H In dichloromethane
With toluene-4-sulfonic acid In tetrahydrofuran at -10 - 10℃; for 1h;

2,2-dimethoxy-propane (77-76-9) + 2-bromo-1-[4-hydroxy-3-(hydroxymethyl)-phenyl]ethanone (62932-94-9) → 2-bromo-1-(2,2-dimethyl-4H-benzo[d][1,3]dioxin-6-yl)ethanone (102293-80-1)

Conditions	Yield
With toluene-4-sulfonic acid In dichloromethane	99%
With toluene-4-sulfonic acid In dichloromethane at 20℃;	84%
In dichloromethane at 20℃; for 10h;	82%

2-Methoxypropene (116-11-0) + N-tert-butylbenzylamine (3378-72-1) + 2-bromo-1-[4-hydroxy-3-(hydroxymethyl)-phenyl]ethanone (62932-94-9) → C23H29NO3

Conditions	Yield
Stage #1: 2-Methoxypropene; 2-bromo-1-[4-hydroxy-3-(hydroxymethyl)-phenyl]ethanone With toluene-4-sulfonic acid In acetone at 0 - 5℃; for 1h; Stage #2: N-tert-butylbenzylamine In acetone at 55℃; for 22h;	80%

2-bromo-1-[4-hydroxy-3-(hydroxymethyl)-phenyl]ethanone (62932-94-9) → (R)-(-)-salmeterol

Conditions

Yield

Multi-step reaction with 5 steps 1.1: resin-SO3H / CH2Cl2 2.1: resin-N(iPr)2 / tetrahydrofuran 3.1: CaCl2 / methanol / 0.17 h / 0 °C 3.2: 76 percent / resin-NMe3(1+)*BH4(1-) / methanol / 2 h / 0 - 20 °C 4.1: (polystyrylmethyl)trimethylammonium cyanoborohydride; AcOH / CH2Cl2 4.2: 98 percent / resin-NMe3(1+)*NaCO3(1-) / CH2Cl2 5.1: H2 / Pd(OH)2/C / ethyl acetate / 2 h 5.2: 87 percent / SCX-2 View Scheme

2-bromo-1-[4-hydroxy-3-(hydroxymethyl)-phenyl]ethanone (62932-94-9) → (1'S)-1-(2,2-dimethyl-4H-benzo[1,3]dioxin-6-yl)-2-(2-hydroxy-1-phenyl-ethylamino)-ethanone (380414-67-5)

Conditions	Yield
Multi-step reaction with 2 steps 1: resin-SO3H / CH2Cl2 2: resin-N(iPr)2 / tetrahydrofuran View Scheme

2-bromo-1-[4-hydroxy-3-(hydroxymethyl)-phenyl]ethanone (62932-94-9) → (1R,1'S)-1-(2,2-dimethyl-4H-benzo[1,3]dioxin-6-yl)-2-(2-hydroxy-1-phenyl-ethylamino)-ethanol (380414-68-6)

Conditions	Yield
Multi-step reaction with 3 steps 1.1: resin-SO3H / CH2Cl2 2.1: resin-N(iPr)2 / tetrahydrofuran 3.1: CaCl2 / methanol / 0.17 h / 0 °C 3.2: 76 percent / resin-NMe3(1+)*BH4(1-) / methanol / 2 h / 0 - 20 °C View Scheme

2-bromo-1-[4-hydroxy-3-(hydroxymethyl)-phenyl]ethanone (62932-94-9) → (1R,1'S)-1-(2,2-dimethyl-4H-benzo[1,3]dioxin-6-yl)-2-{(2-hydroxy-1-phenyl-ethyl)-[6-(4-phenyl-butoxy)-hexyl]-amino}-ethanol (380414-69-7)

Conditions	Yield
Multi-step reaction with 4 steps 1.1: resin-SO3H / CH2Cl2 2.1: resin-N(iPr)2 / tetrahydrofuran 3.1: CaCl2 / methanol / 0.17 h / 0 °C 3.2: 76 percent / resin-NMe3(1+)*BH4(1-) / methanol / 2 h / 0 - 20 °C 4.1: (polystyrylmethyl)trimethylammonium cyanoborohydride; AcOH / CH2Cl2 4.2: 98 percent / resin-NMe3(1+)*NaCO3(1-) / CH2Cl2 View Scheme

2-bromo-1-[4-hydroxy-3-(hydroxymethyl)-phenyl]ethanone (62932-94-9) → 2-{bis-[6-(4-phenyl-butoxy)-hexyl]-amino}-1-(2,2-dimethyl-4H-benzo[1,3]dioxin-6-yl)-ethanol

Conditions	Yield
Multi-step reaction with 4 steps 1.1: resin-SO3H / CH2Cl2 2.1: resin-N(iPr)2 / tetrahydrofuran 3.1: CaCl2 / methanol / 0.17 h / 0 °C 3.2: 76 percent / resin-NMe3(1+)*BH4(1-) / methanol / 2 h / 0 - 20 °C 4.1: H2 / Pd(OH)2/C / ethyl acetate View Scheme

2-bromo-1-[4-hydroxy-3-(hydroxymethyl)-phenyl]ethanone (62932-94-9) → (1S)-2-amino-1-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)ethanol (384340-07-2)

Conditions	Yield
Multi-step reaction with 4 steps 1: 100 percent / TsOH*H2O / CH2Cl2 / 0.67 h / 0 °C 2: 95 percent / NaN3 / dimethylformamide / 2 h / 20 °C 3: 94 percent / Pichia angusta / acetonitrile / 48 h / 28 °C 4: 86 percent / H2 / Pd/C / ethanol / 3 h View Scheme
Multi-step reaction with 4 steps 1: 100 percent / TsOH*H2O / CH2Cl2 / 0.67 h / 0 °C 2: 95 percent / NaN3 / dimethylformamide / 2 h / 20 °C 3: Mucor racemosus / 42 h 4: 86 percent / H2 / Pd/C / ethanol / 3 h View Scheme

2-bromo-1-[4-hydroxy-3-(hydroxymethyl)-phenyl]ethanone (62932-94-9) → 2-azido-1-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)ethanone (384340-05-0)

Conditions	Yield
Multi-step reaction with 2 steps 1: 100 percent / TsOH*H2O / CH2Cl2 / 0.67 h / 0 °C 2: 95 percent / NaN3 / dimethylformamide / 2 h / 20 °C View Scheme

2-bromo-1-[4-hydroxy-3-(hydroxymethyl)-phenyl]ethanone (62932-94-9) → (1S)-2-azido-1-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)ethanol (384340-06-1)

Conditions	Yield
Multi-step reaction with 3 steps 1: 100 percent / TsOH*H2O / CH2Cl2 / 0.67 h / 0 °C 2: 95 percent / NaN3 / dimethylformamide / 2 h / 20 °C 3: 94 percent / Pichia angusta / acetonitrile / 48 h / 28 °C View Scheme
Multi-step reaction with 3 steps 1: 100 percent / TsOH*H2O / CH2Cl2 / 0.67 h / 0 °C 2: 95 percent / NaN3 / dimethylformamide / 2 h / 20 °C 3: Mucor racemosus / 42 h View Scheme

2-bromo-1-[4-hydroxy-3-(hydroxymethyl)-phenyl]ethanone (62932-94-9) → (1R)-2-AZIDO-1-(2,2-DIMETHYL-4H-1,3-BENZODIOXIN-6-YL)ETHANOL (384340-09-4)

Conditions	Yield
Multi-step reaction with 3 steps 1: 100 percent / TsOH*H2O / CH2Cl2 / 0.67 h / 0 °C 2: 95 percent / NaN3 / dimethylformamide / 2 h / 20 °C 3: Mucor racemosus / 42 h View Scheme

2-bromo-1-[4-hydroxy-3-(hydroxymethyl)-phenyl]ethanone (62932-94-9) → (1S)-1-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-{[6-(4-phenylbutoxy)hexyl]amino}ethanol (384340-08-3)

Conditions	Yield
Multi-step reaction with 5 steps 1: 100 percent / TsOH*H2O / CH2Cl2 / 0.67 h / 0 °C 2: 95 percent / NaN3 / dimethylformamide / 2 h / 20 °C 3: 94 percent / Pichia angusta / acetonitrile / 48 h / 28 °C 4: 86 percent / H2 / Pd/C / ethanol / 3 h 5: 70 percent / dimethylformamide / 67 h / 20 °C View Scheme
Multi-step reaction with 5 steps 1: 100 percent / TsOH*H2O / CH2Cl2 / 0.67 h / 0 °C 2: 95 percent / NaN3 / dimethylformamide / 2 h / 20 °C 3: Mucor racemosus / 42 h 4: 86 percent / H2 / Pd/C / ethanol / 3 h 5: 70 percent / dimethylformamide / 67 h / 20 °C View Scheme

2-bromo-1-[4-hydroxy-3-(hydroxymethyl)-phenyl]ethanone (62932-94-9) → (S)-salmeterol acetate

Conditions	Yield
Multi-step reaction with 6 steps 1: 100 percent / TsOH*H2O / CH2Cl2 / 0.67 h / 0 °C 2: 95 percent / NaN3 / dimethylformamide / 2 h / 20 °C 3: 94 percent / Pichia angusta / acetonitrile / 48 h / 28 °C 4: 86 percent / H2 / Pd/C / ethanol / 3 h 5: 70 percent / dimethylformamide / 67 h / 20 °C 6: 100 percent / H2O / 0.5 h / 71 °C View Scheme
Multi-step reaction with 6 steps 1: 100 percent / TsOH*H2O / CH2Cl2 / 0.67 h / 0 °C 2: 95 percent / NaN3 / dimethylformamide / 2 h / 20 °C 3: Mucor racemosus / 42 h 4: 86 percent / H2 / Pd/C / ethanol / 3 h 5: 70 percent / dimethylformamide / 67 h / 20 °C 6: 100 percent / H2O / 0.5 h / 71 °C View Scheme

2-bromo-1-[4-hydroxy-3-(hydroxymethyl)-phenyl]ethanone (62932-94-9) → 2-{bis-[6-(4-phenyl-butoxy)-hexyl]-amino}-1-(2,2-dimethyl-4H-benzo[1,3]dioxin-6-yl)-ethanol

Conditions	Yield
Multi-step reaction with 5 steps 1: 100 percent / TsOH*H2O / CH2Cl2 / 0.67 h / 0 °C 2: 95 percent / NaN3 / dimethylformamide / 2 h / 20 °C 3: 94 percent / Pichia angusta / acetonitrile / 48 h / 28 °C 4: 86 percent / H2 / Pd/C / ethanol / 3 h 5: dimethylformamide / 67 h / 20 °C View Scheme
Multi-step reaction with 5 steps 1: 100 percent / TsOH*H2O / CH2Cl2 / 0.67 h / 0 °C 2: 95 percent / NaN3 / dimethylformamide / 2 h / 20 °C 3: Mucor racemosus / 42 h 4: 86 percent / H2 / Pd/C / ethanol / 3 h 5: dimethylformamide / 67 h / 20 °C View Scheme

2-bromo-1-[4-hydroxy-3-(hydroxymethyl)-phenyl]ethanone (62932-94-9) → 3-(3-(2-(tert-butyldimethylsilyloxy)-2-(2,2-dimethyl-4H-benzo[d][1,3]dioxin-6-yl)ethylamino)propoxy)-N-(3,5-dichloropyridin-4-yl)-4-methoxybenzamide (1424337-27-8)

Conditions	Yield
Multi-step reaction with 4 steps 1: dichloromethane / 10 h / 20 °C 2: sodium tetrahydroborate / methanol / 1 h / 0 - 20 °C 3: 1H-imidazole / N,N-dimethyl-formamide / 16 h / 20 °C 4: triethylamine / N,N-dimethyl-formamide / 24 h / 65 °C View Scheme

2-bromo-1-[4-hydroxy-3-(hydroxymethyl)-phenyl]ethanone (62932-94-9) → 3-(4-(2-(tert-butyldimethylsilyloxy)-2-(2,2-dimethyl-4H-benzo[d][1,3]dioxin-6-yl)ethylamino)butoxy)-N-(3,5-dichloropyridin-4-yl)-4-methoxybenzamide (1424337-28-9)

Conditions	Yield
Multi-step reaction with 4 steps 1: dichloromethane / 10 h / 20 °C 2: sodium tetrahydroborate / methanol / 1 h / 0 - 20 °C 3: 1H-imidazole / N,N-dimethyl-formamide / 16 h / 20 °C 4: triethylamine / N,N-dimethyl-formamide / 24 h / 65 °C View Scheme

2-bromo-1-[4-hydroxy-3-(hydroxymethyl)-phenyl]ethanone (62932-94-9) → 3-(5-(2-(tert-butyldimethylsilyloxy)-2-(2,2-dimethyl-4H-benzo[d][1,3]dioxin-6-yl)ethylamino)pentyloxy)-N-(3,5-dichloropyridin-4-yl)-4-methoxybenzamide (1424337-29-0)

Conditions	Yield
Multi-step reaction with 4 steps 1: dichloromethane / 10 h / 20 °C 2: sodium tetrahydroborate / methanol / 1 h / 0 - 20 °C 3: 1H-imidazole / N,N-dimethyl-formamide / 16 h / 20 °C 4: triethylamine / N,N-dimethyl-formamide / 24 h / 65 °C View Scheme

2-bromo-1-[4-hydroxy-3-(hydroxymethyl)-phenyl]ethanone (62932-94-9) → 3-(6-(2-(tert-butyldimethylsilyloxy)-2-(2,2-dimethyl-4H-benzo[d][1,3]dioxin-6-yl)ethylamino)hexyloxy)-N-(3,5-dichloropyridin-4-yl)-4-methoxybenzamide (1424337-30-3)

Conditions	Yield
Multi-step reaction with 4 steps 1: dichloromethane / 10 h / 20 °C 2: sodium tetrahydroborate / methanol / 1 h / 0 - 20 °C 3: 1H-imidazole / N,N-dimethyl-formamide / 16 h / 20 °C 4: triethylamine / N,N-dimethyl-formamide / 24 h / 65 °C View Scheme

2-bromo-1-[4-hydroxy-3-(hydroxymethyl)-phenyl]ethanone (62932-94-9) → C28H31Cl2N3O6

Conditions	Yield
Multi-step reaction with 5 steps 1: dichloromethane / 10 h / 20 °C 2: sodium tetrahydroborate / methanol / 1 h / 0 - 20 °C 3: 1H-imidazole / N,N-dimethyl-formamide / 16 h / 20 °C 4: triethylamine / N,N-dimethyl-formamide / 24 h / 65 °C 5: ammonium fluoride / water; ethanol / 48 h / 45 °C View Scheme

2-bromo-1-[4-hydroxy-3-(hydroxymethyl)-phenyl]ethanone (62932-94-9) → C29H33Cl2N3O6

Conditions	Yield
Multi-step reaction with 5 steps 1: dichloromethane / 10 h / 20 °C 2: sodium tetrahydroborate / methanol / 1 h / 0 - 20 °C 3: 1H-imidazole / N,N-dimethyl-formamide / 16 h / 20 °C 4: triethylamine / N,N-dimethyl-formamide / 24 h / 65 °C 5: ammonium fluoride / water; ethanol / 48 h / 45 °C View Scheme

2-bromo-1-[4-hydroxy-3-(hydroxymethyl)-phenyl]ethanone (62932-94-9) → C30H35Cl2N3O6

Conditions	Yield
Multi-step reaction with 5 steps 1: dichloromethane / 10 h / 20 °C 2: sodium tetrahydroborate / methanol / 1 h / 0 - 20 °C 3: 1H-imidazole / N,N-dimethyl-formamide / 16 h / 20 °C 4: triethylamine / N,N-dimethyl-formamide / 24 h / 65 °C 5: ammonium fluoride / water; ethanol / 48 h / 45 °C View Scheme

2-bromo-1-[4-hydroxy-3-(hydroxymethyl)-phenyl]ethanone (62932-94-9) → C31H37Cl2N3O6

Conditions	Yield
Multi-step reaction with 5 steps 1: dichloromethane / 10 h / 20 °C 2: sodium tetrahydroborate / methanol / 1 h / 0 - 20 °C 3: 1H-imidazole / N,N-dimethyl-formamide / 16 h / 20 °C 4: triethylamine / N,N-dimethyl-formamide / 24 h / 65 °C 5: ammonium fluoride / water; ethanol / 48 h / 45 °C View Scheme

2-bromo-1-[4-hydroxy-3-(hydroxymethyl)-phenyl]ethanone (62932-94-9) → C25H27Cl2N3O6 (1424337-09-6)

Conditions	Yield
Multi-step reaction with 6 steps 1: dichloromethane / 10 h / 20 °C 2: sodium tetrahydroborate / methanol / 1 h / 0 - 20 °C 3: 1H-imidazole / N,N-dimethyl-formamide / 16 h / 20 °C 4: triethylamine / N,N-dimethyl-formamide / 24 h / 65 °C 5: ammonium fluoride / water; ethanol / 48 h / 45 °C 6: hydrogenchloride / water; ethanol / 12 h / 20 °C View Scheme

2-bromo-1-[4-hydroxy-3-(hydroxymethyl)-phenyl]ethanone (62932-94-9) → C26H29Cl2N3O6 (1424337-10-9)

Conditions	Yield
Multi-step reaction with 6 steps 1: dichloromethane / 10 h / 20 °C 2: sodium tetrahydroborate / methanol / 1 h / 0 - 20 °C 3: 1H-imidazole / N,N-dimethyl-formamide / 16 h / 20 °C 4: triethylamine / N,N-dimethyl-formamide / 24 h / 65 °C 5: ammonium fluoride / water; ethanol / 48 h / 45 °C 6: hydrogenchloride / water; ethanol / 12 h / 20 °C View Scheme

Upstream product

• 24085-07-2 3'-acetoxymethyl-4'-acetoxy-2-bromoacetophenone 
• 24085-06-1 4'-acetoxy-3'-(acetoxymethyl)acetophenone 
• 115787-50-3 5-(2-bromoacetyl)-2-hydroxybenzaldehyde 
• 90-02-8 salicylaldehyde 
• 99-93-4 4-Hydroxyacetophenone 

Downstream Products

• 102293-80-1 2-bromo-1-(2,2-dimethyl-4H-benzo[d][1,3]dioxin-6-yl)ethanone 
• 1444617-09-7 C₂₆H₂₁NO₆ 
• 54208-72-9 2-(tert-butylamino)-1-(2,2-dimethyl-4H-benzo[d][1,3]dioxan-6-yl)ethanol 
• 238762-33-9 C₁₆H₂₅NO₃*C₂₀H₁₈O₈ 
• 380414-69-7 (1R,1'S)-1-(2,2-dimethyl-4H-benzo[1,3]dioxin-6-yl)-2-{(2-hydroxy-1-phenyl-ethyl)-[6-(4-phenyl-butoxy)-hexyl]-amino}-ethanol 
• 380414-68-6 (1R,1'S)-1-(2,2-dimethyl-4H-benzo[1,3]dioxin-6-yl)-2-(2-hydroxy-1-phenyl-ethylamino)-ethanol 

Relevant articles and documents

Synthesis method of salbutamol sulfate intermediate

The invention discloses a synthesis method of a salbutamol sulfate intermediate, which comprises the following steps: by taking salicylaldehyde as a raw material, carrying out three-step reaction of Friedel-Crafts acylation, reduction, propylidene protection and N alkylation, and obtaining the target product salbutamol intermediate with the reaction yield of more than 60% in each step. The synthesis method of the salbutamol sulfate intermediate has the advantages of few reaction steps, simple post-treatment and high product purity.

Method for synthesizing Vilanterol intermediate in mixed solvent

The invention discloses a method for synthesizing a Vilanterol intermediate in a mixed solvent, and belongs to the field of drug synthesis. According to the method, 5-bromoacetyl-2-hydroxybenzaldehydeis reduced by sodium borohydride in the mixed solvent to obtain 2-bromo-1-[4-hydroxy-3-(hydroxymethyl) phenyl] ethyl-1-ketone. Reaction selectivity and yield are improved, post-treatment is simple, and the method is suitable for industrial production.

Levalbuterol intermediate and synthetic method of levalbuterol hydrochloride

The invention provides a levalbuterol intermediate and a levalbuterol hydrochloride synthesis method, and relates to a levalbuterol intermediate and a method for preparing levalbuterol hydrochloride from the intermediate. The method comprises steps as follows: 2-halogenate-1-(2,2-dimelthyl-4-hydrogen-benzo [d][1,3] dioxane)-butanone and organic amine have a Hoffman alkylation reaction to prepare a compound in the formula 2, the structural formula of the compound is shown in the specification, and the compound in the formula 2 is subjected to a reduction reaction, optically pure organic acid resolution and deprotection by hydrochloric acid to obtain levalbuterol hydrochloride. The method does not need processes of protection or deprotection and the like of hydroxyl groups on a benzene ring, protection, deprotection and purification processes are reduced, the synthesis route is short, operation is simple, meanwhile, borane-thioether does not need to be used as a reduction agent, and safety and environmental protection are realized.

Hybrids consisting of the pharmacophores of salmeterol and roflumilast or phthalazinone: Dual β2-adrenoceptor agonists-PDE4 inhibitors for the treatment of COPD

A novel class of dual pharmacology bronchodilators targeting both β2-adrenoceptor and PDE4 was designed and synthesised by combining the pharmacophores of salmeterol and roflumilast or phthalazinone. All the compounds exhibited better β2-adrenoceptor agonist activities (pEC50 = 8.47-9.20) than the reference compound salmeterol (pEC50 = 8.3) and good inhibitory activity on PDE4B2 (IC 50 = 0.235-1.093 μM).

A convenient synthesis of (R)-salmeterol via Rh-catalyzed asymmetric transfer hydrogenation

(R)-Salmeterol was synthesized in eight steps with salicaldehyde as the starting material. The key chiral intermediate, alcohol 5, was prepared via Rh-catalyzed asymmetric transfer hydrogenation with (S,S)-PEG-BsDPEN or (S,S)-TsDPEN ligand and sodium formate as the hydrogen donor under mild conditions.

Synthesis of the β2 Agonist (R)-Salmeterol Using a Sequence of Supported Reagents and Scavenging Agents

(Matrix Presented) The enantioselective synthesis of (R)-salmeterol has been achieved by using a sequence of supported reagents and sequestering agents. The saligenin core was installed by a regiospecific alkylation and a chiral auxiliary approach was employed to introduce the desired stereochemistry via a diastereoselective reduction.

3,4-disubstituted phenylethanolaminotetralincarboxamide derivatives

The present invention relates to 3,4-disubstituted phenylethanolaminotetralincarboxamide derivatives represented by the general formula: STR1 (wherein A represents a lower alkylene group; B represents an amino group, a di(lower alkyl)amino group or a 3 to 7-membered alicyclic amino group which may contain an oxygen atom in the ring; n is an integer of 1 or 2; the carbon atom marked with * represents a carbon atom in R configuration, S configuration or a mixture thereof; and the carbon atom marked with (S) represents a carbon atom in S configuration) and pharmaceutically acceptable salts thereof, which have a selective β 2 -adrenergic receptor stimulating effect with relieved burdens on the heart such as tachycardia and are useful as an agent for the prevention of threatened abortion and premature labor, a bronchodilator and an agent for pain remission and stone removal in urolithiasis.

3,4-disubstituted phenylethanolaminotetralincarboxylic acid derivatives

PCT No. PCT/JP97/01008 Sec. 371 Date Mar. 8, 1999 Sec. 102(e) Date Mar. 8, 1999 PCT Filed Mar. 26, 1997 PCT Pub. No. WO97/35835 PCT Pub. Date Oct. 2, 1997The present invention relates to 3,4-disubstituted phenylethanolaminotetralincarboxylic acid derivatives represented by the general formula: [wherein Q represents a vinylene group or a group represented by the general formula: -A-(CH2)m-(wherein A represents an oxygen atom or a methylene group; and m is an integer of from 1 to 6); R represents a hydrogen atom or a lower alkyl group; n is an integer of 1 or 2; the carbon atom marked with * represents a carbon atom in R configuration, S configuration or a mixture thereof; and the carbon atom marked with (S) represents a carbon atom in S configuration] and pharmaceutically acceptable salts thereof, which have a selective beta 2-adrenergic receptor stimulating effect with relieved burdens on the heart such as tachycardia and are useful as an agent for the prevention of threatened abortion and premature labor, a bronchodilator and an agent for pain remission and promoting stone removal in urolithiasis.